Asparaginase Erwinia Chrysanthemi
drugOn this page
Also known as Erwinase[r] erwinaze[tm]JZP-458Rylazecrisantaspase (INN)
Summary
Asparaginase Erwinia Chrysanthemi (CHEMBL1863514) is an approved enzyme; indicated across 9 conditions including acute lymphoblastic leukemia and b-cell acute lymphoblastic leukemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Enzyme
- Indications: 9 conditions
- Clinical trials: 15
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1863514 |
| Name | Asparaginase Erwinia Chrysanthemi |
| Type | Enzyme |
| Max phase | 4 |
Also known as: Asparaginase erwinia chrysanthemi, Erwinase[r] erwinaze[tm], JZP-458, Rylaze, crisantaspase (INN), ASPARAGINASE ERWINIA CHRYSANTHEMI
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| acute lymphoblastic leukemia | 4 | MONDO:0004967 | EFO:0000220 |
| B-cell acute lymphoblastic leukemia | 4 | MONDO:0004947 | EFO:0000094 |
| leukemia | 3 | MONDO:0005059 | EFO:0000565 |
| acute myeloid leukemia | 3 | MONDO:0018874 | EFO:0000222 |
| myelodysplastic syndrome | 2 | MONDO:0018881 | EFO:0000198 |
| acute biphenotypic leukemia | 2 | MONDO:0020322 | MONDO:0019460 |
| neoplasm | 1 | MONDO:0005070 | MONDO:0004992 |
| lymphoid leukemia | 1 | MONDO:0005402 | EFO:0004289 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 15.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 7 |
| PHASE3 | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
| PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02521493 | PHASE3 | ACTIVE_NOT_RECRUITING | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome |
| NCT03117751 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma |
| NCT03914625 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia |
| NCT04293562 | PHASE3 | RECRUITING | A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations |
| NCT02553460 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I |
| NCT02981628 | PHASE2 | RECRUITING | Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia |
| NCT03164057 | PHASE2 | ACTIVE_NOT_RECRUITING | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia |
| NCT06317662 | PHASE2 | RECRUITING | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia |
| NCT06738368 | PHASE2 | RECRUITING | Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia |
| NCT06918431 | PHASE2 | RECRUITING | Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
| NCT01643408 | PHASE2 | COMPLETED | A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy |
| NCT02723994 | PHASE2 | COMPLETED | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia |
| NCT07133997 | PHASE1 | RECRUITING | Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia |
| NCT07059975 | EARLY_PHASE1 | RECRUITING | UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML |
| NCT04943952 | Not specified | APPROVED_FOR_MARKETING | JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).